GlobeNewswire Clinical StudiesOriginal article
Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome
Phase 2positiveQRX003Positive
AI Analysis
Summary
Quoin Pharmaceuticals reported positive interim Phase 2/3 data for QRX003 in Netherton Syndrome, with the primary endpoint met in four of six patients treated. The positive results support continued development of the candidate therapy.
Clinical Trial Data
Phase
Phase 2/3
Primary Endpoint
Met
Patients
6
Outcome Details
Primary endpoint met with four of six patients responding
Importance:7/10
Sentiment:
0.85
Phase 2/3 dataNetherton Syndromepositive interim resultsrare disease
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on August 28, 2026 10:00 AM